Genzyme Corp. has opened its new Science Center in Framingham, Mass. The facility serves as a central site for early stage research, where scientists are utilizing the most advanced technologies available to discover novel new treatments for devastating diseases such as Parkinson’s, cancer, and heart disease. The company also announced that the Science Center has received a Gold certification under the U.S. Green Building Council’s LEED® (Leadership in Energy and Environmental Design) Green Building Rating System™. It is one of only 10 laboratories to achieve this high rating. “Genzyme exists to innovate, and the Science Center reflects this purpose,” stated Henri A. Termeer, Genzyme’s chairman and chief executive officer. “The work done at this facility will ensure that we can continue to bring forward therapies to significantly improve patients’ lives and will help support the company’s long-term growth. I am so proud of our scientists who discover and make possible life-saving medicines.” Researchers at the Science Center focus on a variety of medical areas including genetic diseases, cancer, immune diseases, kidney disease, cardiovascular disease, endocrinology and neurological disorders. In their work to develop new treatments, they utilize a range of technologies, such as proteins, antibodies, cell therapy and gene therapy. Genzyme’s core R&D operations are located in Framingham. Genzyme also has an R&D site in Waltham, Mass., for polymer and small molecule research and a facility in Cambridge, U.K., focused on monoclonal antibody research.